154422-95-4

Upstream product

• 194669-41-5 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 578-57-4 2-bromoanisole 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 201609-28-1 1-t-Butoxycarbonyl-4-hydroxy-4-(2-methoxyphenyl)piperidine 

Downstream Products

• 437998-47-5 2-{4-[4-(2-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butyrylamino}-benzamide 
• 58333-75-8 4-(2-methoxyphenyl)piperidine 
• 1552303-62-4 C₂₇H₃₆BrNO₃ 
• 1552303-61-3 C₂₇H₃₄BrNO₃ 
• 1422444-24-3 C₂₃H₂₃N₃O₃ 
• 277296-73-8 cyclohexanecarboxylic acid{(1R)-2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-1-pyridin-4-ylmethyl-ethyl}-methyl-amide 
• 277296-71-6 cyclohexanecarboxylic acid {(1R)-2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-1-pyridin-3-ylmethyl-ethyl}-methyl-amide 
• 277296-87-4 C₂₅H₃₁N₃O₄ 

Relevant academic research and scientific papers

Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker

To obtain an optimized T-type calcium channel blocker with reduced off-target hERG toxicity, we modified the structure of the original compound by introducing a zwitterion and reducing the basicity of the nitrogen. Among the structurally modified compound

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Tetrahydrobenzindole compounds

A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4and R5and n are as defined in the specification.